<code id='1207664B81'></code><style id='1207664B81'></style>
    • <acronym id='1207664B81'></acronym>
      <center id='1207664B81'><center id='1207664B81'><tfoot id='1207664B81'></tfoot></center><abbr id='1207664B81'><dir id='1207664B81'><tfoot id='1207664B81'></tfoot><noframes id='1207664B81'>

    • <optgroup id='1207664B81'><strike id='1207664B81'><sup id='1207664B81'></sup></strike><code id='1207664B81'></code></optgroup>
        1. <b id='1207664B81'><label id='1207664B81'><select id='1207664B81'><dt id='1207664B81'><span id='1207664B81'></span></dt></select></label></b><u id='1207664B81'></u>
          <i id='1207664B81'><strike id='1207664B81'><tt id='1207664B81'><pre id='1207664B81'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:leisure time    Page View:725
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In